Rallybio
Merged with Candid Therapeutics and now trades under NASDAQ: CDRX
Developing transformative therapies for devastating rare diseases.
Sector
Life SciencesCategory
TherapeuticsLocation
Farmington, CTInitial Investment
2020
Developing transformative therapies for devastating rare diseases.
Rallybio is a biopharmaceutical company focused on identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Rallybio merged with Candid Therapeutics in 2026. The combined company will operate as Candid Therapeutics and trade on NASDAQ under the ticker CDRX.